Pharmacogenetics and the future of medical practice

被引:29
作者
Lindpaintner, K [1 ]
机构
[1] F Hoffmann La Roche, Roche Genet, CH-4070 Basel, Switzerland
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2003年 / 81卷 / 03期
关键词
pharmacogenetics; pharmacogenomics; single nucleotide polymorphism; polymorphism; gene variant;
D O I
10.1007/s00109-002-0416-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pharmacogenetics is today widely proclaimed to be about to revolutionize the face of medicine. In a more realistic assessment, the implementation of molecular genetics and biology will continue to provide us, as it has done already, with better ways to diagnose and treat illnesses, but it will do so at a stepwise and evolutionary pace, based on an improved understanding of the nature of disease, allowing more specific treatments, better risk prediction, and the implementation of preventive strategies. As such, future progress in biomedicine will travel the same well-trodden paths of improved differential diagnosis and risk prediction along which it has advanced in the past decades and centuries. Thus, while meaningful biomedical research today by and large depends on the use of the newly developed tools of genetics and genomics and the insights that we gain through them, it is unlikely fundamentally to change the direction of medical progress.
引用
收藏
页码:141 / 153
页数:13
相关论文
共 24 条
[1]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[2]   Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].
Dean, M ;
Carrington, M ;
Winkler, C ;
Huttley, GA ;
Smith, MW ;
Allikmets, R ;
Goedert, JJ ;
Buchbinder, SP ;
Vittinghoff, E ;
Gomperts, E ;
Donfield, S ;
Vlahov, D ;
Kaslow, R ;
Saah, A ;
Rinaldo, C ;
Detels, R ;
OBrien, SJ .
SCIENCE, 1996, 273 (5283) :1856-1862
[3]  
Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442
[4]  
DICKINS M, 2001, INT J PHARM MED, V15, P70
[5]   Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].
Drazen, JM ;
Yandava, CN ;
Dubé, L ;
Szczerback, N ;
Hippensteel, R ;
Pillari, A ;
Israel, E ;
Schork, N ;
Silverman, ES ;
Katz, DA ;
Drajesk, J .
NATURE GENETICS, 1999, 22 (02) :168-170
[6]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[7]   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[8]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[9]   Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].
Fellay, J ;
Marzolini, C ;
Meaden, ER ;
Back, DJ ;
Buclin, T ;
Chave, JP ;
Decosterd, LA ;
Furrer, H ;
Opravil, M ;
Pantaleo, G ;
Retelska, D ;
Ruiz, L ;
Schinkel, AH ;
Vernazza, P ;
Eap, CB ;
Telenti, A .
LANCET, 2002, 359 (9300) :30-36
[10]   Genetic factors in aminoglycoside toxicity [J].
Fischel-Ghodsian, N .
OTOTOXICITY: BASIC SCIENCE AND CLINICAL APPLICATIONS, 1999, 884 :99-109